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Dependence on the 26S proteasome is an Achilles’ heel for triple-
negative breast cancer (TNBC) andmultiple myeloma (MM). The ther-
apeutic proteasome inhibitor, bortezomib, successfully targets MM
but often leads to drug-resistant disease relapse and fails in breast
cancer. Here we show that a 26S proteasome-regulating kinase,
DYRK2, is a therapeutic target for both MM and TNBC. Genome
editing or small-molecule mediated inhibition of DYRK2 significantly
reduces 26S proteasome activity, bypasses bortezomib resistance,
and dramatically delays in vivo tumor growth in MM and TNBC
thereby promoting survival. We further characterized the ability of
LDN192960, a potent and selective DYRK2-inhibitor, to alleviate tu-
mor burden in vivo. The drug docks into the active site of DYRK2 and
partially inhibits all 3 core peptidase activities of the proteasome.
Our results suggest that targeting 26S proteasome regulators will
pave the way for therapeutic strategies in MM and TNBC.
DYRK | multiple myeloma | triple-negative breast cancer | kinase
inhibitor | proteasome inhibitor
Multiple myeloma (MM) and triple-negative breast cancer(TNBC) are diverse forms of neoplasia with a combined
predicted incidence of >70,000 new cases in the United States
with >16,000 deaths in 2018 (American Cancer Society 2018
Facts and Figures). MM arises from clonal proliferation of ma-
lignant plasma cells (1, 2), whereas TNBC is a highly metastatic
form of breast cancer resistant to most hormone therapies due to
a lack of estrogen, progesterone, and HER2 receptors (3). Al-
though with no apparent similarities in physiological manifesta-
tions or current pharmacological interventions, both MM and
TNBC are surprisingly dependent on the 26S proteasome function
for survival and progression of disease (2, 4). The 26S proteasome
is an essential protein complex that degrades the majority of cel-
lular proteins in eukaryotes (5). The 20S core particle harbors the
intrinsic chymotryptic (β5), tryptic (β2), and caspase-like (β1)
peptidase activities, whereas the remaining subunits (RPT1–6,
RPN1–3, 5–13, and 15) constitute a 19S regulatory particle that
caps the 20S core and plays a role in ubiquitylated-substrate re-
cruitment, unfolding, and translocation (5, 6).
The malignant plasma cells in MM are Ig secreting factories (4)
and require the proteasome to play a vital role in ER-associated
elimination of misfolded proteins for survival and progression
(2, 7). FDA-approved drugs bortezomib, carfilzomib, and ixazomib
directly bind to and inhibit the 20S core peptidase active site and
alleviate MM progression thereby improving life expectancy of
patients (2, 8), albeit with reported side effects (9). However, the
20S core subunits frequently accumulate mutations and/or in-
crease copy number (10); when this happens, these patients may
develop bortezomib resistance (11). There are limited options
when patients exhibit relapsed or refractory MM coupled with
proteasome-inhibitor resistance (12).
TNBC, on the other hand, exhibits a high rate of disease re-
lapse with a marked dependence on the 26S proteasome function
(4), but unlike MM, the 26S proteasome in TNBC functions to
systematically degrade proapoptotic factors leading to neoplastic
survival and malignant progression (4). Despite the proteasome
dependence, proteasome inhibitors have shown modest efficacy
in breast cancer and other solid tumors (13, 14) either due to
poor drug penetration into the solid tumors (4) or insufficient
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potency of the drugs to inhibit all 3 core peptidases of the 20S
proteasome (15).
Due to the dependence on 26S proteasome function in both
forms of neoplasia and the shortcomings of current proteasome
inhibitors, we need novel strategies to target the Achilles’ heel
of MM and TNBC. The 26S proteasome has >300 conserved
phosphorylation sites on its various subunits, yet very few kinases
or phosphatases that regulate the phosphorylation state of these
sites have been reported thus far (16–18). Our laboratory
recently identified dual-specificity tyrosine phosphorylation-
regulated kinase 2 or DYRK2 as a bona fide proteasome regu-
lating kinase that phosphorylates Thr25 on RPT3 and leads to
enhanced proteasome activity (17). Inhibition of DYRK2-mediated
phosphorylation of RPT3 causes a dramatic reduction in all 3
peptidase activities of the 26S proteasome leading to a marked
reduction in the rate of protein degradation, thereby impeding
cell cycle progression thus reducing tumor growth (17, 19). As a
proof of concept, we recently reported that the natural product
curcumin, derived from turmeric, is a highly potent and selective
inhibitor of DYRK2 that sensitized both MM and TNBC cell
lines via partial inhibition of proteasome activity (19). Further-
more, bortezomib-resistant MM cells were equally sensitive to
DYRK2 inhibition as compared to standard MM lines, thus
suggesting that inhibiting DYRK2 is a viable therapeutic option
for drug-resistant MM patients (19).
In the current study, we report a highly potent and selective
small-molecule inhibitor of DYRK2, LDN192960, which allevi-
ates neoplastic progression in both MM and TNBC. Our results
establish that inhibition of DYRK2 is a therapeutic strategy to
target dual 26S proteasome-adapted MM and TNBC progres-
sion leading to impediment of malignancy and potential im-
provement of patient survival.
Results
DYRK2 and Proteasome Subunits Are Up-Regulated in TNBC. To es-
tablish DYRK2 as a viable target for TNBC treatment, we ex-
amined the differential expression status of DYRK2 in TNBC
patient tissues. Immunohistochemistry of DYRK2 on patient-
derived TNBC tumors showed a higher expression of DYRK2 in
malignancy relative to adjacent normal breast tissues (Fig. 1A).
TNBC is known to be highly heterogeneous, so a bioinformatic
approach was undertaken to more comprehensively evaluate the
expression status of DYRK2; the DYRK2 substrate RPT3; and
the proteasome core subunit, PSMB5, in TNBC diseased states.
PSMB5, the core 20S proteasome subunit β5, harbors the
chymotryptic-like activity of the proteasome and is known to be
overexpressed and/or mutated in malignancy (10, 20–22). We
mined the TCGA Cancer Genome Atlas (https://www.cancer.
gov/); downloaded the gene expression data of all cancer types
and matched normal tissue controls (where available); and
compared DYRK2, RPT3, and PSMB5 gene expression (SI
Appendix, Fig. S1). As reported previously, DYRK2 expression
was largely cancer type specific (17), although in the majority of
cancers, we find DYRK2 to be overexpressed compared to
normal controls (SI Appendix, Fig. S1 and Table S1). Specifically,
in the 1,204 breast cancer patients, DYRK2 was overexpressed
relative to matched normal controls (SI Appendix, Fig. S1).
Within the breast cancer database, we identified 115 TNBC
patients annotated with 11 matched normal tissue controls
wherein DYRK2 expression was significantly up-regulated (*P <
0.05) (Fig. 1B). Both RPT3 and PSMB5 were also significantly
overexpressed (***P < 0.001) (Fig. 1 C and D).
The proteasome was isolated from MDA-MB-468 parental
cells or DYRK2-depleted cells using overexpressed TEV-Biotin-
HA tagged RPN11 (RPN11-TBHA) as bait. The proteasome
activity was measured on the pull-downs using the Suc-LLVY-
AMC substrate peptide. DYRK2 knock-out (KO) cells had 30%
reduced proteasome activity (Fig. 1E).
To establish the role of DYRK2 in TNBC, we generated
DYRK2-depleted MDA-MB-231 cells and developed a mam-
mary fat pad-derived breast cancer xenograft model in athymic
nude mice J:NU (Fig. 1F). DYRK2 depletion led to significant
tumor burden reduction in the mice xenografts which was com-
pletely restored in mice bearing DYRK2-depleted cells reintro-
duced with wild-type DYRK2 (Fig. 1 G and H). In fact, the loss
of proliferating cells in the tumor as measured by Ki67 staining
was also rescued in the DYRK2-reintroduced tumors (Fig. 1I).
These data suggest that DYRK2 inhibition could indeed be a
promising mechanism for inhibiting the TNBC proteasome.
DYRK2 Promotes MM Progression.We examined whether MM also
exhibited a similar overexpression pattern for DYRK2 and
proteasome subunits as in TNBC (Fig. 1 B–D). We queried a
publicly available dataset, GSE6477 (https://www.ncbi.nlm.nih.
gov/geo/, GSE6477) (23, 24), for the differential expression of
DYRK2, RPT3, and PSMB5 between normal and newly
diagnosed MM disease states. Similar to TNBC, we found sig-
nificant overexpression of all 3 genes (Fig. 2 A–C) suggesting the
DYRK2 is indeed a potential target in MM. We depleted
DYRK2 in MM cell lines using Crispr/Cas9. DYRK2 depletion
was ascertained by anti-DYRK2 immunoblotting with GAPDH
as a control (Fig. 2D). To further quantify the proteasome ac-
tivity, cell lysates from parental and DYRK2-depleted MM cells
were assayed with the fluorogenic peptide substrate, Suc-LLVY-
AMC. DYRK2-depleted cells exhibited a 30 to 40% decrease in
Fig. 1. DYRK2 and proteasome are up-regulated in TNBC and promote
tumor progression. (A) DYRK2 IHC of TNBC and adjacent normal breast tis-
sue sections from patients. (Scale bar, 100 μm.) (B) DYRK2, (C) RPT3, and (D)
PSMB5 differential gene expression in human TNBC and matched normal
tissue as available from TCGA (TNBC vs. normal tissue, P value derived from a
semipaired modification to the Student’s t test) (see also SI Appendix, Fig.
S1). (E) Proteasome was affinity-purified from 1 mg of cell lysate of parental
or DYRK2 KO MDA-MB-468 Rpn11-TBHA cells. Proteasome activity was
measured with Suc-LLVY-AMC. **P < 0.01 (parental vs. DYRK2 KO, unpaired
Student’s t test, mean ± SD from n = 3 independent experiments). Immu-
noblotting of the cell lysates were carried out with indicated antibodies. (F)
Experimental flow for TNBC xenograft study in G–I. (G and H) MDA-MB-231
parental or DYRK2 KO or DYRK2 KO +WT rescue cells were injected into the
mammary fat pad of J:NU nude mice. Tumor volume was measured twice a
week (n = 6 mice per condition), and growth curves were plotted. ***P <
0.001 (compared to parental group, 2-way ANOVA, mean ± SD with Tukey’s
multiple comparison). (I) Histological examination of consecutive sections of
the tumors (from G and H) with Ki67 and hematoxylin/eosin staining. (Scale
bar, 100 μm.)
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proteasome activity in both murine (MPC11 and 5TGM1-GFP)
and human (MM.1S) MM cells (Fig. 2D).
Next, we carried out proliferation assays to compare the rate
of proliferation between parental and genome-edited MPC11
and 5TGM1-GFP cells. Consistent with our previous data, upon
DYRK2 depletion, the rate of proliferation of both cell lines was
significantly diminished over 5 d (Fig. 2 E and F).
DYRK2 promotes tumorigenesis in mouse xenograft models
(17, 19). However, the exact role of DYRK2 in tumorigenesis in
diverse cancer models is unclear (17, 25–29). To ascertain the
role of DYRK2 in MM neoplastic progression and survival, we
utilized a syngeneic MM model. MPC11 (Merwin plasma cell
tumor 11) cells were derived from a plasmacytoma from the
BALB/c strain of mice (30). We injected either parental or
DYRK2-depleted MPC11 via tail vein into BALB/c mice of ei-
ther sex, 10 mice for each cell strain. The main disease mani-
festation of MM has been termed CRAB for hypercalcemia,
renal dysfunction, anemia, and bone degeneration (31, 32).
MPC11-BALB/c syngeneic allografts are an established model
for MM exhibiting bone degeneration 14 to 21 d postinjection
(33). In our study, disease progression in mice was observed by
movement difficulties leading to hindlimb paralysis. Moribund
mice exhibiting complete hindlimb paralysis were killed, and
Kaplan–Meier survival curves were generated to compare pa-
rental and DYRK2-depleted allograft-bearing mice. BALB/c
mice with DYRK2-depleted MPC11 cells had a prolonged
(>30%) delay in terminal MM disease progression (Fig. 2 G
and H).
To study the effect of DYRK2 depletion on MM-mediated
bone degeneration, MPC11 parental or DYRK2-depleted allograft-
bearing BALB/c mice were killed 3 wk postinjection (Fig. 2I).
Micro computed tomography (μCT) imaging was carried out to
visualize cortical and trabecular bone structure on the formalin-
fixed excised femurs. Quantitative analysis of the trabecular
bone of the proximal femur region revealed that the averaged
proximal femur trabecular parameters for DYRK2-depleted
allograft-bearing mice were significantly higher in percent tra-
becular bone volume, with significantly higher bone mineral
density and higher trabecular number than parental allo-
grafts (Fig. 2 J–M). Similar studies were carried out using the
5TGM1-GFP myeloma model (34). NSG mice were i.v. injected
with either vector control or DYRK2-depleted 5TGM1-GFP
cells (SI Appendix, Fig. S2 A and B). Mice were killed 3 wk
postinjection, and femurs were excised. The femurs from mice
bearing DYRK2-depleted cells had substantially fewer GFP+
foci (SI Appendix, Fig. S2 C and D), and femur cross section
staining revealed significantly lower tartrate-resistant acid
phosphatase activity signifying lower osteoclast activity (SI Ap-
pendix, Fig. S2E).
Thus, our data establish DYRK2 as a kinase that promotes
MM cell proliferation and disease progression, which lead to
accelerated malignancy and morbidity in vivo.
LDN192960 Is a Potent and Selective Inhibitor of DYRK2. Because
DYRK2 clearly plays an oncogenic role in TNBC and MM, we
hypothesized that a small-molecule inhibitor for DYRK2 could
Fig. 2. DYRK2 promotes myeloma progression and myeloma-mediated bone degeneration. (A) DYRK2, (B) RPT3, and (C) PSMB5 differential gene expression
analyses were performed on the MM dataset with the accession number GSE6477 available at the Gene Expression Omnibus (myeloma vs. normal tissue, P
value derived from empirical Bayes estimation on linear models of gene expression in limma package) (see also SI Appendix, Fig. S3). (D) Proteasome activity in
total cell lysates from indicated MM parental and DYRK2 KO cells was measured with Suc-LLVY-AMC and normalized to total protein content. **P < 0.01
(parental vs. DYRK2 KO, unpaired Student’s t test, mean ± SD from n = 3 independent experiments). Immunoblotting of the cell lysates was carried out with
indicated antibodies. (E and F) Growth curves of myeloma cell lines MPC11 and 5TGM1-GFP (parental and DYRK2 KO). *P < 0.05, **P < 0.01 (2-way ANOVA,
mean ± SD from n = 3 independent experiments). (G) Experimental flow for myeloma allograft survival study in H. (H) MPC11 parental or DYRK2 KO cells
were injected i.v. into BALB/c mice (n = 10 per condition). Moribund mice with complete hindlimb paralysis were killed, and the Kaplan–Meier curve was
derived (P value derived from survival curve comparison using Mantel–Cox Log-rank test). (I) Experimental flow for myeloma allograft study in J–M. (J) MPC11
parental or DYRK2 KO cells were injected i.v. into BALB/c mice (n = 6 per condition). Three weeks postinjection, mice were killed, and μCT imaging was carried
out on formalin-fixed femur bone. Representative μCT image is shown. (Scale bar, 600 μm.) (K–M) Post-μCT the percentage of proximal femur trabecular bone
volume over total volume (K), proximal femur bone mineral density (L), and proximal femur trabecular number (M) were quantified. *P < 0.05 (parental vs.
DYRK2 KO, unpaired Student’s t test, mean ± SD from n = 6 mice).
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PH
A
RM
A
CO
LO
G
Y
potentially alleviate cancer progression. We recently reported
that curcumin is a potent and selective inhibitor of DYRK2 (19).
However, curcumin is highly hydrophobic, shows activity in vivo
at high 300 mg/kg body weight, and in general is termed as an
improbable drug (35). Hence, we identified LDN192960 (Fig.
3A) as a potential inhibitor of DYRK2. LDN192960 was de-
veloped initially as a Haspin inhibitor and was found to exhibit
off-target effects on DYRK and PIM isoforms (36, 37).
LDN192960 had an in vitro IC50 of 13 nM toward DYRK2 at
50 μM ATP and exhibits a 0.5- to 4-fold change in DYRK2 IC50
upon titration of 10 to 300 μM ATP (Fig. 3B). Kinetically, it
exhibits a mixed mode of DYRK2 inhibition (SI Appendix, Fig.
S4). To evaluate whether LDN192960 could suppress cellular
DYRK2 activity, we treated HEK293T cells transiently over-
expressing DYRK2-FLAG with increasing concentrations of
LDN192960 and assessed RPT3 phosphorylation at Thr25, the
major site of DYRK2 phosphorylation on the proteasome. We
observed that LDN192960 treatment suppressed Thr25 RPT3
phosphorylation in a dose-dependent manner, with maximal ef-
fects observed at inhibitor concentrations of 1 to 10 μM (Fig.
3C). Furthermore, other than PIM and DYRK isoforms (Fig.
3D), LDN192960 does not inhibit any of the 130+ kinases tested
to the same extent including other CMGC kinase family mem-
bers that are closely related to the DYRKs (Fig. 3E).
To elucidate how LDN192960 specifically inhibits DYRK2,
we crystallized DYRK2 in complex with LDN192960 and
Fig. 3. LDN192960 is a potent and selective inhibitor of DYRK2. (A) Chemical structure of LDN192960. (B) In vitro IC50 of LDN192960 on purified DYRK2 over 3
different ATP concentrations. Results are means ± SD for triplicate reactions with similar results obtained in at least 1 other experiment (see also SI Appendix,
Fig. S4). (C) HEK293T cells transiently expressing DYRK2 were treated with the indicated concentrations of LDN192960 over 2 h. Cells were lysed, and im-
munoblotting was carried out with the indicated antibodies. (D) Table listing IC50 values for indicated kinases for LDN192960. (E) Kinase profiling of
LDN192960 at 1 μMwas carried out against the panel of 140 kinases at the International Centre for Protein Kinase Profiling (http://www.kinase-screen.mrc.ac.uk/).
(F) A composite omit map is contoured at 1.5 σ and shown as an orange mesh, revealing the presence of LDN192960 and 2 water molecules (red spheres).
DYRK2 is shown as ribbons and colored in gray. PDB ID 6K0J. (G) LDN192960 occupies the ATP-binding pocket of DYRK2. DYRK2 is shown in a surface
representation, and LDN192960 atoms are shown as spheres. (H) Detailed interactions between DYRK2 and LDN192960. Hydrogen bonds are shown as dashed
lines (see also SI Appendix, Fig. S5 and Table S2).
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determined the structure at 2.35 Å (Fig. 3F and SI Appendix,
Table S1). LDN192960 binds to the ATP-binding pocket of
DYRK2 (Fig. 3G). It is sandwiched between several hydrophobic
DYRK2 residues, including Ala249, Ile285, Phe301, Leu355, and
Ile367 (Fig. 3H). One of the methoxy groups of LDN192960
forms a hydrogen bond with the main chain amide group
Leu304. Two water molecules are also seen in the pocket and
mediate a network of hydrogen bonds between LDN192960 and
DYRK2 residues Glu266, Asp368, and Phe369. The amino side
chain of LDN192960 extends out and forms a hydrogen bond
with the main chain carbonyl group of Glu352 (Fig. 3H).
Together, these biochemical and structural data suggest that
LDN192960 targets the ATP binding active site of DYRK2 and
specifically inhibits DYRK2 kinase activity in vitro and in cells.
LDN192960 Impedes 26S Proteasome Activity in Cells and Induces
Cytotoxicity. LDN192960 treatment results in significant re-
duction of all 3 (β1, β2, and β5) peptidase activities of the pro-
teasome as seen by using specific fluorogenic peptide substrates
(Fig. 4A). Moreover, MM and TNBC cells treated with LDN192960
exhibit a 20 to 40% inhibition of proteasome activity (Fig. 4B).
Furthermore, a combination of LDN192960 with either ixazomib
or carfilzomib exhibited a modest additive effect toward the
inhibition of proteasome activity (Fig. 4C). Interestingly, 1 μM
LDN192960 significantly affected the proliferation of MDA-
MB-468 parental cells unlike the MDA-MB-468 DYRK2 KO
or RPT3 Thr25Ala knock-in cells where 1 μM LDN192960 had a
modest effect on proliferation (Fig. 4D). Similarly, LDN192960
inhibited cell proliferation in both MM cells tested (Fig. 4E).
LDN192960 exhibits cytotoxicity to all MM cells tested with an
EC50 between 1 and 10 μM; however, noncancerous AHH1 cells
exhibited resistance >30 μM EC50 to LDN192960-mediated cy-
totoxicity (Fig. 4F). Similarly, all TNBC cells tested exhibited an
LDN192960 EC50 of 1 to 10 μM (Fig. 4G). Treatment with 3 μM
LDN192960 largely reduced the ability of MDA-MB-231 cells
to invade in 3D matrigel invasion chemotaxis assays (Fig. 4H)
to a similar extent as curcumin (19). Interestingly, 1 to 3 μM
LDN192960 treatment markedly suppressed the ability of
TNBC cells to form anchorage-independent 3D growth (Fig. 4
I–K). Next, we wanted to determine if LDN192960-ixazomib
mediated additive impairment of proteasome activity (Fig.
4C) could have an effect on cancer cell viability. Interestingly, a
marked additive cytotoxicity was observed in proteasome addicted
MM cell line MM.1S, whereas noncancerous cells AHH1, FT190,
FT240, MCF10A, and 184B5 did not exhibit additive cytotoxicity
upon treatment with LDN192960 and ixazomib (Fig. 4L). Fur-
thermore, 1 and 5 μM LDN192960 induced more pronounced
cytotoxicity in MDA-MB-468 parental cells as compared to
MDA-MB-468 DYRK2 KO or RPT3 Thr25Ala knock-in cells
(Fig. 4M).
We next queried whether LDN192960 could in fact inhibit
DYRK2-mediated proteasome function in primary patient-
derived CD138+ MM cells and whether LDN192960-mediated
cytotoxicity is specific for CD138+ MM cells compared to non-
cancerous peripheral blood mononuclear cells (PBMC). CD138+
MM cells were purified from the bone marrow aspirates of MM
patients, and PBMCs were either purified from patient periph-
eral blood or purchased from ATCC. Postpurification, equal
numbers of CD138+ MM cells were treated with DMSO or
LDN192960. Interestingly, CD138+ cells were relatively more
sensitive to 3 μM LDN192960 treatment for 24 h compared to
the PBMC counterparts (Fig. 4N). Furthermore, upon treatment
with 10 μM LDN192960 for 2 h, the CD138+ cell lysate exhibited
a significant reduction of proteasome activity as compared to the
DMSO control lysate (Fig. 4O).
Thus, LDN192960 impairs major hallmarks of cancer cells via
partial inhibition of proteasome activity.
LDN192960 Delays MM Progression and Impedes Myeloma-Mediated
Bone Degeneration. We have shown that mice bearing MPC11
DYRK2 KO cells develop a much slower MM burden and
consequently present better bone health relative to the parental
counterparts (Fig. 2 F–I). To determine if LDN192960 treatment
could inhibit bone degeneration in mice bearing parental MPC11
similar to the DYRK2 KO phenotype, we generated the synge-
neic MPC11-BALB/c mouse allograft model. Parental cell-
bearing mice were randomized into 2 groups for thrice weekly
treatment with either PBS vehicle or 50 mg/kg LDN192960 (Fig.
5A). MPC11-DYRK2 KO–bearing mice were generated in par-
allel for comparison (no treatment). All mice were killed after
3 wk of treatment. The femurs were excised, formalin fixed, and
imaged by μCT to visualize cortical and trabecular bone struc-
ture. Compared to vehicle-treated controls, both LDN192960-
treated and DYRK2 KO-bearing mice exhibited comparable
higher bone trabecular network (Fig. 5B). At the trabecular
region, both the LDN192960-treated group and the DYRK2
KO-bearing group showed significantly higher trabecular bone
volume fraction, bone mineral density, and trabecular number
than the vehicle-treated cohort (Fig. 5 C–E).
We know from our previous studies that DYRK2 KO cells do
not exhibit further reduction of proteasome activity upon treat-
ment with DYRK2 inhibitor (19). However, we understand that
LDN192960 also inhibits PIM kinases, which have been known
to be targets in MM (38, 39); hence, we wanted to ascertain the
relative contributions of DYRK2 versus other kinases toward the
in vivo effects observed with LDN192960 treatment. We gener-
ated an s.c. xenograft model by injecting MM.1S cells (parental
or DYRK2 KO) into nude J:NU mice and investigated whether
LDN192960 treatment could further reduce MM tumors in the
absence of DYRK2 (Fig. 5F). Upon palpable tumor formation,
parental and DYRK2 KO-bearing mice were randomized each
into 2 groups and treated with vehicle or LDN192960 50 mg/kg.
There was a dramatic reduction of tumor volume in parental
xenografts upon LDN192960 treatment (Fig. 5 G and H) and a
clear reduction of 26S proteasome activity in the tumor lysate as
well (Fig. 5I). In DYRK2 KO-bearing xenografts, there was a
modest but nonsignificant tumor reduction in volume and weight
with LDN192960 treatment (Fig. 5 G and H). In addition,
LDN192960 treatment improved survival of mice allografted
with 5TGM1-GFP cells (Fig. 5 J and K) with mean survival 28.5
d as compared to 19 d for vehicle treated. Furthermore, there
was no significant decrease in body weights of mice observed
after 3× 50 mg/kg doses of LDN192960 (Fig. 5L).
Thus, our data indicate that LDN192960 can effectively
impede MM cell growth in vivo via DYRK2 inhibition.
LDN192960 Inhibits Bortezomib-Resistant MM. Bortezomib re-
sistance is a major therapeutic impediment for MM patients (2).
Various studies have reported diverse reasons for why malignant
plasma cells develop bortezomib resistance. Plasma cells have
been reported to develop bortezomib resistance by reducing
misfolded protein levels and ER stress during differentiation,
thereby uncoupling from the dependence on the proteasome
(40). Other groups point to overexpression, polyploidy, and
bortezomib-docking site mutations of the proteasome to be key
for developing bortezomib resistance (10, 20–22). Interestingly,
there was a modest yet statistically significant overexpression of
DYRK2 in the relapsed MM patient sample dataset compared
with newly diagnosed MM controls (Fig. 6A) along with RPT3
and PSMB5 which were overexpressed as well in the same
GSE6477 dataset (SI Appendix, Fig. S3). Because DYRK2 is an
upstream regulator of the 26S proteasome, we hypothesized that
it may very well serve as a therapeutic target even in relapsed
MM. To test this, we used bortezomib-resistant cell lines that
were generated by adaptation to continuous proteasome inhibition
(19, 41). RPMI8226.BR and MM.1S.BR cells exhibited >10- to
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Fig. 4. LDN192960 perturbs proteasome activity, induces cell death, and impedes proliferation and invasion. (A) Proteasome activity in total cell lysates from MDA-
MB-468 cells with or without 10 μM LDN192960 treatment for 2 h was measured with Suc-LLVY-AMC or Ac-RLR-AMC or Ac-GPLD-AMC. *P < 0.05, **P < 0.01
(compared to control treated, 2-tailed paired Student’s t test, mean ± SD from n = 3 biological replicates). (B) Proteasome activity in total cell lysates from the
indicated cells with or without 10 μM LDN192960 treatment for 2 h was measured with Suc-LLVY-AMC and normalized to total protein content. **P < 0.01
(compared to control treated for each cell line, ordinary 1-way ANOVA, mean ± SD from n = 3 independent experiments). (C) MDA-MB-231 cells were pretreated
with indicated drugs (Ixa, Ixazomib; Cz, Carfilzomib; LDN, LDN192960) for 1 h, and proteasome activity was measured in cell lysates using Suc-LLVY-AMC. **P < 0.01,
*P < 0.05 (compared to control treated, ordinary 1-way ANOVA, mean ± SD from n = 3 independent experiments). Immunoblotting of the cell lysates was carried out
with indicated antibodies. (D) Fold proliferation of MDA-MB-468WT, DYRK2 KO, and RPT3 Thr25Ala knock-in cells in presence of DMSO control or 1 μM LDN192960.
***P < 0.001 (2-way ANOVA, mean ± SD from n = 3 biological replicates). (E) Growth curves of MM.1S and 5TGM1-GFP control and LDN192960-treated cells (MM.1S
1 μM and 5TGM1-GFP 3 μM). **P < 0.01, ***P < 0.001 (2-way ANOVA, mean ± SD from n = 3 independent experiments). (F and G) LDN192960 induces cytotoxicity in
all myeloma (F) and TNBC (G) tested with EC50 between 6 and 12 μM. Noncancerous AHH-1 cells had >30 μM EC50 for LDN192960. LDN192960 treatment was carried
out for 36 h for this experiment. (H) Bar graph depicting cell invasion in a Matrigel transwell migration assay using DMSO treated or 3 μM curcumin or LDN192960-
treated MDA-MB-231 cells. Data were acquired 18 h after seeding in upper chamber of 8 μm pore size transwells. Cells that invaded the Matrigel were quantified
based on DNA content using CyQuant dye and data represented as arbitrary units (a.u.). **P < 0.01, ***P < 0.001 (compared to DMSO treated, 2-way ANOVA,
mean ± SD from n = 2 independent experiments with triplicates in each). (I–K) Growth in 3D culture. MDA-MB-468 (I), MDA-MB-231 (J), and EO771 (K) cells were
cultured in 1%methylcellulose for 2 to 4 wk in the presence of DMSO or LDN192960 at 1 or 3 μM. Areas of cell growth were quantified by analysis of images (5 per
well). ****P < 0.0001 (compared to DMSO treated, 2-way ANOVA, mean ± SD from n = 2 independent experiments with triplicates in each). (L) Proteasome addicted
MM.1S cells and noncancerous AHH1, FT190, FT240, MCF10A, and 184B5 cells were treated with ixazomib alone (MCF10A, 184B5, andMM.1S = 25 nM; FT190, FT240,
and AHH1 = 50 nM) or with LDN192960 alone (FT190, FT240, MCF10A, and 184B5 = 5 μM; AHH1 = 10 μM; MM.1S = 3 μM) or the combination of ixazomib and
LDN192960 for 24 h, and cell viability was analyzed by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. Viability of DMSO-treated cells was utilized
as control. Data are represented as fold viability of DMSO-treated control for each cell line (# indicates statistical significance compared to each single drug treatment;
2-way ANOVA with multiple comparison, Fisher’s LSD test) (see also SI Appendix, Fig. S6). (M) MDA-MB-468 parental, DYRK2 KO, and RPT3 Thr25Ala knock-in cells
were treated with or without LDN192960 at the indicated concentrations for 48 h. Cell viability was ascertained with CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay kit. Data were represented as percent viable compared to DMSO-treated cells. (N) Purified primary patient CD138+myeloma and PBM cells were
treated with 3 μM of LDN192960 or DMSO control for 24 h, and cell viability was ascertained with CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit.
Data were represented as percent viable compared to DMSO-treated cells (PBMC from ATCC was used as control for patient 1 due to nonavailability of peripheral
blood). (O) Proteasome activity in lysates from primary patient CD138+myeloma cells treated with DMSO or 10 μM LDN192960 for 2 h was measured with Suc-LLVY-
AMC. *P < 0.05 (compared to control treated, 2-tailed paired Student’s t test, mean ± SD from n = 3 independent replicates).
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50-fold resistance to bortezomib compared with the respective
bortezomib-sensitive parental RPMI8226 and MM.1S cells (Fig.
6 B and C). However, the EC50 for LDN192960 for either pa-
rental or bortezomib-resistant lines of the MM cells were identical
(Fig. 6D), suggesting that LDN192960-mediated cytotoxicity is
independent of bortezomib resistance. Furthermore, LDN192960
perturbed the proteasome activity of both 8226.BR andMM.1S.BR
cells by 30 to 40% (Fig. 6E), similar to standard MM cells (Fig. 4B).
To further confirm the antitumor efficacy of LDN192960 in
targeting bortezomib-resistant tumors, parental and bortezomib-
resistant RPMI8226 cells were injected s.c. in J:NU mice (Fig.
6F). Mice with palpable tumors were randomized into 2 groups
and injected intraperitoneally thrice weekly with either vehicle
control or 50 mg/kg LDN192960. Indeed, LDN192960 treat-
ment significantly reduced tumor burden in bortezomib-resistant
RPMI8226.BR lines after 2 wk of treatment comparable to the
level in parental RPMI8226 (Fig. 6 G and H). Interestingly,
8226.BR cells had a significantly higher proteasome activity than
8226 WT cells without any change in 20S or 19S RPT3 protein
levels (Fig. 6I). However, 8226.BR cells had markedly higher
DYRK2 and pT25 RPT3 signals which possibly contribute to the
higher proteasome activity (Fig. 6I).
Thus, our data suggest that LDN192960 induces cytotoxicity in
bortezomib-resistant MM, both in cells and in vivo.
Fig. 5. LDN192960 impedes MM progression and delays myeloma-mediated bone degeneration. (A and B) MPC11 parental or genome edited (DYRK2 KO)
cells were injected i.v. into inbred BALB/c mice (n = 12 for parental and n = 6 for DYRK2 KO). Two weeks postinjection, parental cell-bearing mice were
randomized into 2 groups of n = 6 and treated with vehicle PBS or LDN192960 50 mg/kg thrice weekly. Two weeks posttreatment, the mice were killed, and
formalin-fixed femur bones were imaged using μCT. Representative μCT image is shown. (Scale bar, 600 μm.) (C–E) Post-μCT the bone mineral density (C), the
percentage of trabecular bone volume over total volume (D), and the trabecular number (E) were quantified for distal and proximal femurs. *P < 0.05, **P <
0.01 (compared to vehicle treated, 1-way ANOVA, mean ± SD, multiple comparisons with Fisher’s LSD test, from n = 6 mice each). (F) Experimental flow for
MM.1S myeloma xenograft study in G. (G) MM.1S parental or genome-edited (DYRK2 KO) cells were injected s.c. into J:NU nude mice. Palpable tumor-bearing
mice were randomized (16 d for parental and 28 d for DYRK2 KO) into 2 equal groups each and treated with vehicle control or LDN192960 3 times a week by
i.p. injection, and tumor volume was measure twice a week. **P < 0.01 (compared to parental vehicle-treated group, 2-way ANOVA, mean ± SD from n = 5
mice each). (H) Post-42 d of injection, tumors were resected, and tumor weight was measured. ***P < 0.001, ns, not significant (compared to vehicle treated,
ordinary 1-way ANOVA, mean ± SD from n = 5 mice each). (I) Proteasome activity in whole tumor lysates from parental vehicle or LDN192960-treated tumor-
bearing mice was measured with Suc-LLVY-AMC. **P < 0.01 (compared to control treated, 2-tailed paired Student’s t test, mean ± SD from n = 3 different
tumors each). (J) Experimental flow for 5TGM1-GFP myeloma allograft study in K. (K) 5TGM1-GFP cells were injected i.v. into J:NU mice and treated with
50 mg/kg LDN192960 or vehicle 14 d postinjection (n = 12 per condition). Moribund mice with complete hindlimb paralysis were killed, and Kaplan–Meier curve
was derived (P value derived from survival curve comparison using Mantel–Cox Log-rank test). (L) Weight of mice before and after 3× 50 mg/kg LDN1929060
treatment (P value derived from Student’s t test, mean ± SD from n = 12 mice).
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LDN192960 Markedly Reduces TNBC Tumor Burden. Recent work has
shown that simultaneous inhibition of both β5 chymotryptic-like
and β2 tryptic-like subunits of the proteasome is essential to
sensitize TNBC (15). Since LDN192960-mediated DYRK2 in-
hibition perturbed all 3 core peptidase activities of the protea-
some (Fig. 4A) and genetic depletion of DYRK2 led to
reduction of TNBC tumors in mice (Fig. 1 G–I), we wanted to
test the antitumor efficacy of the drug at targeting the solid tu-
mor in vivo.
We evaluated the effect of LDN192960 in 3 different TNBC
allo/xenograft models. Parental MDA-MB-231 mice with pal-
pable mammary tumors were randomized into 2 groups and
treated with either vehicle control or 50 mg/kg LDN192960 (Fig.
7A). Interestingly, there was a very dramatic tumor reduction
after 2 wk of LDN192960 treatment, manifested by slower tumor
growth (Fig. 7B) and reduced proteasome activity in the resected
tumor lysates (Fig. 7H). To test the efficacy of LDN192960 in a
primary TNBC patient-derived sample, we developed a patient-
derived xenograft (PDX) model from fresh frozen tissues ac-
quired from the University of California San Diego (UCSD)
Moores Cancer Center Biorepository (Fig. 7C). PDX97 was
derived from the primary tumor with grade 3 invasive triple-
negative ductal carcinoma. Treatment of 50 mg/kg LDN192960
significantly reduced the tumor burden of J:NU mice bearing
PDX97 tumors (Fig. 7D), along with a reduced proteasome ac-
tivity in the resected tumor lysates (Fig. 7H).
To further confirm this in a syngeneic TNBC model, we
employed the basal-like TNBC cell line EO771, which was de-
rived from a spontaneously developed medullary breast adeno-
carcinoma in C57BL/6 mice (42). We injected EO771 cells into
the mammary fat pad of virgin female C57BL/6J mice and ran-
domized palpable tumor-bearing mice into 2 groups followed by
treatment with LDN192960 or DMSO as previously described
(Fig. 7E). After 2 wk of treatment, the tumor growth rate of the
LDN192960-treated cohort was significantly slower than vehicle-
treated (Fig. 7F) with a marked reduction in Ki67 stained pro-
liferating cells (Fig. 7G). We also observed a modest increase in
proteasome substrates p27 and IκBα protein levels in LDN192960-
treated tumor lysates (Fig. 7G) and a reduced proteasome activity
in the tumor lysates (Fig. 7H).
Thus, LDN192960-mediated inhibition of DYRK2 signifi-
cantly alleviates tumor burden in standard and PDX TNBC
models, and partial inhibition of the proteasome contributes to
this anti-TNBC tumor activity.
Discussion
The ubiquitin–proteasome system has long been the focus for
development of clinical therapeutics in cancer, including but not
limited to targeting deubiquitinases (43), manipulating E3 ligases
(44), and inhibiting 19S subunits (45) and the 20S core (11) of
the proteasome. Our work opens a possibility of inhibiting ki-
nases playing a vital role in molecular regulation of the 26S
proteasome. With over 300 phosphorylation sites on a 4.5-MDa
complex with nearly 40 subunits, identifying kinases and phos-
phatases regulating the 26S proteasome could be the next novel
paradigm for development of alternate mechanisms of targeting
proteasome-inhibitor resistant or relapsed neoplasias.
Our current work proposes an alternate mechanism of targeting
proteasome-addicted malignancies via perturbing upstream regu-
lators of the 26S proteasome. We established DYRK2 as a bona
fide proteasome kinase and showed that DYRK2 inhibition leads
to impediment of the cell cycle via accumulation of proteasome
substrates and proapoptotic factors leading to tumor regression
(17, 19). In this study, we report that DYRK2 is overexpressed and
promotes both TNBC (Fig. 1) and MM (Fig. 2) progression. We
further report LDN192960 as a potent and selective small-
molecule inhibitor of DYRK2 (Fig. 3) that induced cytotoxicity
and growth inhibition in MM and TNBC cells with relatively
modest effects in noncancerous lines (Fig. 4). LDN192960 re-
stricted MM-mediated bone degeneration (Fig. 5) and bypassed
bortezomib resistance in MM (Fig. 6). LDN192960 further
reduced tumor burden in TNBC mouse allo/xenografts, and
LDN192960-treated tumors exhibited partial inhibition of
Fig. 6. LDN192960 bypasses bortezomib resistance. (A) DYRK2 differential gene expression in human relapsed MM specimens and human normal tissue as
available from a public database GSE6477 (relapsed vs. normal tissue, P value derived from empirical Bayes estimation on linear models of gene expression in
limma package) (see also SI Appendix, Fig. S3). (B and C) Bortezomib EC50 for parental MM.1S and bortezomib-resistant MM.1S.BR cells (B) and for parental
RPMI8226 and bortezomib-resistant 8226.BR cells (C). (D) LDN192960 EC50 for parental MM.1S, parental RPMI8226, MM.1S.BR, and 8226.BR cells. (E) Pro-
teasome activity in total cell lysates from the indicated bortezomib-resistant cells with or without 10 μM LDN192960 treatment for 2 h was measured with Suc-
LLVY-AMC and normalized to total protein content. **P < 0.01 (compared to control treated for each cell line, ordinary 1-way ANOVA, mean ± SD from n = 3
independent experiments). (F) Experimental flow for myeloma xenograft study in G and H. (G and H) The 8226 parental (G) or 8226.BR (H) cells were injected
s.c. into J:NU nude mice. Palpable tumor-bearing mice were randomized (16 d for parental and 23 d for 8226.BR) into 2 equal groups each and treated with
vehicle control or LDN192960 3 times a week by i.p. injection, and tumor volume was measured twice a week (n = 5 per condition). **P < 0.01 (compared to
vehicle treated, 2-way ANOVA, mean ± SD, from n = 5 mice). (I) Proteasome activity in total cell lysates from 8226 WT or 8226.BR was measured with Suc-
LLVY-AMC. **P < 0.01 (8226 WT vs. 8226.BR, unpaired Student’s t test, mean ± SD from n = 3 independent experiments). Immunoblotting of the cell lysates
was carried out with indicated antibodies.
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proteasome activity and a modest accumulation of proteasome
substrates p27 and IκBα (Fig. 7).
Targeting the proteasome has been a major success story
in MM therapeutics with multiple FDA-approved drugs cur-
rently used as front-line defenses (8). However, high incidence of
proteasome-inhibitor resistance leaves patients with limited
clinical options (11). The average 5-y survival rate for MM pa-
tients is only 50% (NCI), which highlights the need for
novel MM therapeutics. Our work provides inroads into phar-
macologically alleviating MM progression via inhibition of
DYRK2. DYRK2 is overexpressed in both newly diagnosed MM
and relapsed MM (Figs. 2A and 6A and SI Appendix, Fig. S3A),
and inhibiting DYRK2 delays myeloma progress, even in
bortezomib-resistant cases (Fig. 6). In addition, DYRK2 depletion/
inhibition halts bone degeneration and promotes overall survival
(Figs. 2 and 5 and SI Appendix, Fig. S2).
Recent work has shown that simultaneous inhibition of both
β5 chymotryptic-like and β2 tryptic-like subunits of the protea-
some is essential to sensitize TNBC (15). Since DYRK2 has
higher expression in TNBC (Fig. 1 A and B) and can indirectly
regulate all 3 peptidase activities of the proteasome (Fig. 4A),
inhibiting the kinase could provide a novel mechanism of
proteasome-directed therapeutics which has largely failed to
date in TNBC clinical trials (13). The success of this concept was
clearly demonstrated by the dramatic reduction in tumor volume
upon genetic depletion (Fig. 1 G–I) or pharmacological in-
hibition of DYRK2 in TNBC allo/xenograft models (Fig. 7).
We further show that DYRK2 can be readily inhibited in vivo
as the DYRK2 inhibitor, LDN192960, directly phenocopies
DYRK2 genetic depletion and alleviates MM (Figs. 2 J–M and
5 B–E) and TNBC (Figs. 1 G–I and 7) progression. LDN192960
is an acridine-orange derivative (36, 37) and largely functions via
specific inhibition of DYRK2 in vitro (Fig. 3), in cells (Figs. 4 A–C
and O and 6E), and in vivo (Figs. 5I and 7H). LDN192960 has
a 13-nM IC50 at 50 μM ATP in vitro and binds to the ATP
binding site of DYRK2 via multiple hydrophobic interactions
(Fig. 3 B and F–H) exhibiting a mixed mechanism of DYRK2
inhibition (SI Appendix, Fig. S4) that requires further bio-
chemical dissection beyond the scope of this manuscript. In
particular, Ile285 and Ile367 are involved in making strong
hydrophobic/van der Waals interactions with LDN192960 and play
crucial roles in determining the binding specificity because both
residues are replaced by valines in DYRK1 (Val222 and Val306)
(SI Appendix, Fig. S5). Indeed, LDN192960 showed a 9- to 10-
fold selectivity toward DYRK2 compared to DYRK1A (Fig.
3D). The drug did exhibit in vitro off-target effects on PIM
isoforms and DYRK3 (Fig. 3 D and E), both of which have been
reported to be potentially oncogenic (38, 39, 46). However, tu-
mors derived from DYRK2 KO cells did not show a significant
reduction upon LDN192960 treatment (Fig. 5 G–I). DYRK2
phosphorylates a single site, Thr25, on the N terminus of RPT3
(Fig. 3C), and ablating this phosphorylation perturbs 20 to 40%
proteasome activity in both cells (Figs. 1E, 4 A–C and O, and 6E)
and tumors (Figs. 5I and 7H). LDN192960 did not affect the rate
of proliferation (Fig. 4D) or percent viability of cells (Fig. 4M)
harboring either DYRK2 depletion or RPT3 Thr25Ala knock-in
as compared to parental lines. Interestingly, LDN192960 treat-
ment led to a significant accumulation (****P < 0.001) of
asynchronous cells into the G2-M stage of the cell cycle consis-
tent with our previous studies with DYRK2 KO cells (SI Ap-
pendix, Fig. S6). Furthermore, the additive effect of LDN192960
and the proteasome inhibitors carfilzomib or Ixazomib on pro-
teasome activity in MDA-MB-468 cells (Fig. 4C) was not seen in
the cell viabilities of noncancerous myeloid (AHH1), fallopian
tube epithelial (FT190 and FT240), or mammary (MCF10A and
184B5) lines (Fig. 4L). Interestingly, CD138+ primary patient-
derived myeloma cells were more sensitive to LDN192960 than
matched normal PBMCs isolated from peripheral blood (Fig.
4N). Together, these data suggest a significant portion of
LDN192960’s anticancer activity is through the DYRK2-
proteasome inhibition especially in proteasome addicted can-
cers. However, higher concentrations of LDN192960 do affect
the viability of all cells tested including DYRK2 KO/RPT3 KI
(Fig. 4 F and M); hence, we cannot completely rule out potential
off-target effects on other DYRK2 substrates or other DYRK/
PIM isoforms contributing to antitumor effects exhibited by
higher concentrations of LDN192960. Thus, LDN192960 has a
more pronounced cytotoxic effect toward cancer cells, relative to
noncancerous ones (Figs. 4 F, L and N and 6 B–D), and dra-
matically perturbs 3D invasion through Matrigel matrix (Fig. 4H)
and anchorage-independent 3D growth (Fig. 4 I–K) suggesting a
potential therapeutic window for specific cancer targeting.
It is quite interesting how phosphorylation of a single site
(Thr25) on RPT3 by DYRK2 could perturb 20 to 40% of the 26S
proteasome activity. Cryo-EM structures reveal that the 19S
proteasome-regulatory particle is conformationally dynamic (47,
48), and binding of the ubiquitinated substrate induces broad
rearrangement in the regulatory particle that aligns multiple
subunits including the deubiquitinase RPN11 and hexameric-
ATPase ring with the entrance to the 20S core (48). This rear-
rangement is concomitant upon a 25° rotation of RPN2 about
the RPT3-RPT6 coiled-coil region and allows the proteasome to
enter a substrate-induced degradation mode (48). Since pThr25
Fig. 7. LDN192960 perturbs TNBC progression. (A) Experimental flow for
TNBC xenograft study in B. (B) MDA-MB-231 parental cells were injected into
the mammary fat pad of J:NU nude mice. Palpable tumor-bearing mice were
randomized into 2 equal groups and treated with vehicle control or
LDN192960 3 times a week by i.p. injection, and tumor volume was mea-
sured twice a week (n = 6 per condition). ***P < 0.001 (compared to vehicle
treated, 2-way ANOVA, mean ± SD, from n = 6 mice). (C) Experimental flow
for TNBC PDX study in D. (D) Patient-derived PDX97 tumor specimens were
surgically implanted s.c. into J:NU mice. Palpable tumor-bearing mice were
randomized into 2 equal groups and were treated with vehicle control or
LDN192960 as in B (n = 10 per condition). **P < 0.01 (compared to vehicle
treated, 2-way ANOVA, mean ± SD, from n = 10 mice). (E) Experimental flow
for TNBC allograft study in F. (F) EO771 parental cells were injected into the
mammary fat pad of C57BL/6 immunocompetent mice. Palpable tumor-
bearing mice were randomized into 2 equal groups and were treated with
vehicle control or LDN192960 as in B (n = 11 per condition). **P < 0.01, *P <
0.05 (compared to vehicle treated, 2-way ANOVA, mean ± SD, from n = 11
mice). (G) Immunoblotting with indicated antibodies in tumor lysates from F
and histological examination of consecutive sections of the fixed tumors
from Fwith Ki67 and hematoxylin/eosin staining were carried out. (Scale bar,
100 μm.) (H) Proteasome activity in whole tumor lysates from vehicle or
LDN192960-treated tumor-bearing mice from B, D, and F were measured
with Suc-LLVY-AMC. **P < 0.01 (compared to control treated, 2-way
ANOVA, mean ± SD from n = 3 different tumors each).
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is at the N terminus of the coiled coil, we speculate that it may
facilitate these molecular motions by providing interactions be-
tween RPN2 and RPT3 that favor structural rearrangement to-
ward the degradation-competent mode of the proteasome.
The role of DYRK2 in cancer has been controversial espe-
cially in breast and liver cancers (25–29). We do appreciate that
DYRK2 function could be cancer type and cell type specific, yet
in the context of breast and liver hepatocellular carcinoma co-
horts, we saw strong DYRK2 overexpression (SI Appendix, Fig.
S1 and Table S1). In fact, with a few exceptions, DYRK2 is
significantly overexpressed (*P < 0.05) in many of the cancer
types listed in TCGA as compared to matched normal tissue
controls (SI Appendix, Fig. S1 and Table S1). In addition, IHC
staining in patient TNBC samples with adjacent normal tissue
showed a stronger IHC signal for DYRK2 in diseased state
compared to normal (Fig. 1A). Various pan-DYRK inhibitors
also exhibit antitumor activity (19, 49, 50), which further cor-
roborates the role of DYRK2 as tumor promoting.
In fact, both DYRK2 protein expression and proteasome ac-
tivity were significantly increased in bortezomib-resistant mye-
loma 8226.BR compared to the parental 8226.WT without any
increase in proteasome levels (Fig. 6I). The stoichiometry of
pThr25 signal is quite low (17); however, higher DYRK2 levels
in 8226.BR cells led to a stronger endogenous pThr25 signal in
these cells further suggesting an interesting correlation between
DYRK2 and proteasome activation in neoplasia. Further work is
needed to establish whether DYRK2 is a key player driving
bortezomib resistance disease recurrence.
In the United States alone, nearly 4,000 TNBC and over
12,000 MM (the majority with bortezomib resistance) patient
deaths were projected by the American Cancer Society 2018
Facts and Figures. Development of DYRK2 inhibitors with high
in vivo potency and selectivity could indeed pave the way for
a new option in proteasome-based therapeutics. Targeting
DYRK2 could potentially be beneficial in treating other 26S
proteasome-addicted neoplasia like mantle cell lymphoma where
a partial inhibition of the 3 core peptidase activities of the
proteasome could specifically tip the scales for cancer and
thereby alleviate tumor burden in patients often with relapsed–
refractory disease.
Materials and Methods
For details of general methods, proteasome assays, cell-based assays, mouse
experiments, CD138+ myeloma and PBMC purification, histology, crystal-
lography, kinase specificity screening, bioinformatic analyses, statistics and
data representation, key resources table, and other methods, please refer to
SI Appendix. Crystallography coordinates are deposited in the Protein Data
Bank (PDB; ID 6K0J), and all data in the manuscript are available freely
to readers. Bone marrow aspirates and matched peripheral blood samples
were obtained from Health Insurance Portability and Accountability Act
(HIPAA)-compliant deidentified consenting patients in accordance with
Institutional Review Board approved protocols at University of California
San Diego (UCSD).
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